Streetwise Expert Interviews

Michael May

How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM

There's a new kind of incubator in town. The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian nonprofit that fosters hands-on association between academia, government, industry and investors to grow stem cell and regenerative medicine companies from the ground up. In this interview with The Life Sciences Report, CCRM President and CEO Michael May guides us through the process that brings ideas out of academia and adds the essential nurturing elements to get startups off the ground and into commercial development. Along the way, he mentions a few names that may interest investors.

(4/23/15) More >
Read More Streetwise Interviews

How to Profit from Australia's Healthiest Biotechs: Wilson HTM's Shane Storey

Shane Storey, head of research at Australia-based Wilson HTM Investment Group, observes that as the market value of resource commodities declines, investors are diverting investment capital to healthcare stocks, especially in the medical technology sector. With names that don't come close to their long-term fair valuation potential, the upside for investors could be quite dramatic. (4/16/15) More >

Newsletter Briefs

"RP has a diversified portfolio of technologies, is very focused and is growing rapidly." (4/23/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Michael May More >

"IPD's business model is one we know and love; there is a lot of upside in this company." (4/16/15) ImpediMed Ltd. - The Life Sciences Report Interview with Shane Storey More >

"If MSB's cells work, we're talking about a multibillion-dollar, druglike, blockbuster CHF treatment." (4/8/15) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert More >

"STEM is doing pioneering work in the field of cervical spinal cord Injury and dry age-related macular degeneration." (4/8/15) StemCells Inc. - The Life Sciences Report Interview with Jason Kolbert More >

"We view Omidria sales as a means for OMER to fund one of the most exciting biotechnology pipelines in the industry." (4/8/15) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >

"The longer INO holds onto VGX-3100, the greater the value proposition." (4/8/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Kolbert More >

"Modest penetration into this market could make ATHX's MultiStem more than a $1B product." (4/8/15) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >

"INO's idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating." (3/25/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jill Wahleithner More >

Expert Analysis

"Positive results could position BCLI for NurOwn approval and launch by 2019." (4/21/15) BrainStorm Cell Therapeutics Inc. - Jason Kolbert, Maxim Group More >

"We believe the RNN story is underexposed and the shares undervalued." (4/21/15) Rexahn Pharmaceuticals Inc. - Yale Jen, Laidlaw & Company More >

"INO's INO-1800 for HBV will be evaluated with and without INO-9112." (4/21/15) Inovio Pharmaceuticals Inc. - Charles Duncan, Piper Jaffray & Co. More >

"We raised our 2015 revenue projections for NHC to $314M (from $235M)." (4/20/15) Nobilis Health Corp. - Keith Hinton, Sidoti & Company More >

"We are initiating coverage on RP with a Speculative Buy rating." (4/20/15) RepliCel Life Sciences Inc. - Douglas Loe, Euro Pacific Canada More >

"STEM expects to release six-month interim Phase 2 data later this year." (4/16/15) StemCells Inc. - Henry McCusker, Regenerative Medicine Investors More >

"We maintain an Outperform rating for SNGX." (4/14/15) Soligenix Inc. - Grant Zeng, Zacks Equity Research More >

"OMER's OMS-721 was approved for compassionate use in Europe." (4/14/15) Omeros Corp. - Jason Kolbert, Maxim Group More >